Sign Up to like & get
recommendations!
2
Published in 2022 at "Neuro-oncology"
DOI: 10.1093/neuonc/noac197
Abstract: BACKGROUND IDH1/2 wildtype (IDHwt) glioma WHO grade 2 and 3 patients with pTERT mutation and/or EGFR amplification and/or +7/-10 chromosome gain/loss have a similar overall survival time as IDHwt glioblastoma patients, and are both considered…
read more here.
Keywords:
idh1 wildtype;
glioblastoma;
course;
idhwt glioblastoma ... See more keywords